Company Update (NYSE:PFE): Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™ (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease

[Business Wire] – Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the U.S. Food and Drug Administration approved ELELYSO™ for injection for pediatric patients. Read more on this. Pfizer Inc. (PFE), . . . → Read More: Company Update (NYSE:PFE): Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™ (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease Similar Articles: Market Update (NYSE:LLY): New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies Market Update (NYSE:PFE): Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine Market Update (NYSE:PFE): Pfizer Enters Into Agreement to Acquire Baxter’s Portfolio of Marketed Vaccines